By focusing too heavily on family history, the Preventive Services Task Force is missing many opportunities for prevention, patient advocates, industry players, and researchers say.
Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.
The researchers are developing a web-based tool to help physicians predict their patients' relapse risk and are planning clinical trials to study outcomes.
The company will launch a clinical version of its liquid biopsy assay in the second quarter and plans to launch clinical trials that make the case for reimbursement.
Epigenomics terminated a licensing contract related to Chinese distribution rights for its Septin9 biomarker and Epi proColon colorectal cancer blood test.
The company ran 668,600 tests during the year, a 30 percent increase from its 2017 testing volume.
The VA decided to bring this testing in house to streamline and standardize the process for doctors and gauge markers that are relevant to the veteran population.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The deal will focus on Biocartis' Idylla MSI test, which provides information on a tumor's microsatellite instability status of a tumor from a single FFPE slice.
The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer.
With retrospective and prospective analyses on women with BRCA1/2 mutations, investigators began teasing out breast cancer risk relative to reproductive history.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
The agency said it is sensitive to stakeholder concerns and is working with MACs to adjust claims processing systems.
MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.
Though the firm saw lower overall revenue, it increased its fourth quarter and full-year product and services revenue by 12 percent and 16 percent respectively.
Genomic and transcriptomic data for almost 500 triple-negative breast cancer cases revealed four expression subtypes and suspected treatment targets.
Healthcare providers continue to worry about the impact of 23andMe's health risk reports but there is also growing acceptance of the DTC testing model.
Analyzing mutational signatures in cancer cell lines and xenografts, investigators identified mutagenic processes that do or don't remain active in vitro.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.